A major hurdle in successful utilization of these drugs in the treatment of breast cancer is our lack of understanding at what drives this dichotomy—what makes some AR positive tumors behave so differently and respond in such a different way to the same treatment? This evidence concerns the gene AR and breast carcinoma.